Pre-Launch Activities Importation Request (PLAIR)

PLAIR, or Pre-Launch Activities Importation Request, is a program managed by the U.S. Food and Drug Administration (FDA) through the Center for Drug Evaluation and Research (CDER). It allows drug manufacturers to import finished dosage form drug products into the U.S. before the drug has received final FDA approval—on the assumption that approval is anticipated shortly.

This program helps companies prepare for a timely commercial launch by allowing early-stage warehousing or minimal processing (e.g., labeling) of the unapproved drug while the application (NDA, ANDA, or BLA) is still under FDA review.

Why Is PLAIR Important?

  1. Accelerates Market Readiness
    2. The pharmaceutical industry is highly competitive. Once a drug is approved, being able to distribute it immediately can be a market differentiator. PLAIR helps companies avoid delays caused by post-approval manufacturing and shipping.
  1. Reduces Supply Chain Risk
    2. PLAIR allows manufacturers to manage import logistics, warehousing, and downstream distribution in advance. This means fewer supply chain disruptions and better preparedness.
  1. Ensures Regulatory Compliance
    2. Under Section 505(a) of the Federal Food, Drug, and Cosmetic Act (FD&C Act), unapproved drugs cannot be introduced into interstate commerce. PLAIR provides a compliant framework to legally import such products before approval, without requiring FDA Form 766 for reconditioning.
  1. Supports Efficient Launch Planning
    2. With PLAIR, companies can initiate final packaging or labeling in U.S. facilities, align with marketing teams, and synchronize commercial launch activities.

What Products Are Eligible?

PLAIR applies to finished dosage form drug products associated with:
  • A pending New Drug Application (NDA)
  • A pending Abbreviated New Drug Application (ANDA)
  • Or a Biologic License Application (BLA) regulated by CDER
These products must be either:
In final packaged form, or Require minimal further processing (e.g., labeling or final packaging)

What Products Are Not Eligible for PLAIR?

Active Pharmaceutical Ingredients (APIs)
Raw materials or bulk drug substances that are not in finished dosage form are not eligible under PLAIR.
Products Regulated by CBER
Biologic products under the jurisdiction of the Center for Biologics Evaluation and Research (CBER)—including many vaccines, gene therapies, and blood products—are excluded. PLAIR is strictly for CDER-regulated products.
Medical Devices and Certain Combination Products
Products primarily regulated as medical devices or combination products reviewed under the Center for Devices and Radiological Health (CDRH) or CBER do not qualify.
Investigational Drugs
Drugs intended for use in clinical trials under an Investigational New Drug (IND) application are not eligible. These are regulated through a separate investigational framework.
Products Requiring Substantial Post-Import Processing
PLAIR permits only minimal activities such as final packaging or labeling. Products needing significant manufacturing, formulation, or chemical modification after importation are ineligible.

How to File a PLAIR

Filing a PLAIR involves several procedural steps and specific documentation. Here’s an overview:
  1. When to Submit
    2. Submit the PLAIR at least 30 days prior to the proposed importation date. Additionally:
    • For standard reviews: Submit no more than 60 days before the PDUFA or GDUFA goal date.
    • For priority reviews: Submit up to 120 days before the goal date (NDA/BLA) or 80 days (ANDA).
  1. Where and How to Submit
    2. As of 2024, PLAIR requests are filed electronically via the CDER NexGen Portal. This portal supports real-time communication, multi-factor authentication, and document tracking. Email submission is also possible via CDER-OC-PLAIR@fda.hhs.gov in PDF format, using company letterhead and clearly identifying the application number and drug name.
  1. What to Include in a PLAIR
    2. A complete PLAIR must contain:
    • Drug product name, dosage form, and strength
    • FDA-assigned application number (NDA, ANDA, or BLA)
    • Assigned Regulatory Project Manager (RPM)
    • FDA goal date letter
    • National Drug Code (NDC) if available
    • Manufacturer and U.S. consignee contact info and registration numbers
    • Quantity of product to be imported (limited to one shipment per PLAIR)
    • Details of storage and/or minimal processing facilities
    • A signed statement acknowledging the product is unapproved and subject to reconditioning upon approval
  1. What Happens Next?
    2. Once submitted:
    • CDER reviews the PLAIR and inspects the foreign facility’s compliance history (especially cGMP).
    • If granted, the drug can be detained at the port for up to 6 months, awaiting FDA’s final approval of the application.
    • Upon approval, FDA issues a “Release after Detention.”
    • If the drug is not approved, the product must be exported or destroyed within 90 days.

Why Work with Masuu Global Quality and Regulatory Consultants?

At Masuu Global, we understand the complexities of PLAIR filings and the importance of seamless regulatory execution. Our team of experts offers:
  • Full PLAIR preparation and submission services
  • Regulatory strategy support to align PLAIR timelines with FDA review cycles
  • FDA communication and follow-up on your behalf
  • Inspection readiness and facility compliance assessment
  • Labeling and packaging support for minimal processing sites

Whether you’re a U.S.-based sponsor or a global pharmaceutical manufacturer planning a market launch, Masuu Global Quality and Regulatory Consultants can help streamline the process and mitigate risk.

Book a Demo